Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McGill University

$90,000.00

Epigenetic and transcriptional reprogramming of hematopoietic stem cells as a driver of rheumatoid arthritis onset and progression

FY 2023-24

Summary
Rheumatoid arthritis (RA) affects 1 out of every 100 adult Canadians. RA is an autoimmune disease where the body's tissues are mistakenly attacked by their own immune cells. Anyone can develop RA and at any age, although it affects three times more women than men. RA causes chronic and painful inflammation of the joints, but can also damage other parts of the body (lungs, heart, arteries) to impair quality of life and shorten lifespan. Effective treatments of RA control inflammation but are not curative; some RA patients do not improve with treatment. We aim to determine the biological mechanisms that drive inflammation and trigger RA in patients, as a way to provide new therapeutic options for these patients. We will address this problem in a new way by looking for defects in hematopoietic stem and progenitor cells (HSCs)-cells that continuously replenish our pool of mature immune cells. Therefore, if mature immune cells carry over defects from their earlier predecessors, could they be responsible for causing inflammation in RA? Could we treat RA by correcting these dysfunctional, re-wired HSCs? I propose to tackle this problem differently, together with patients and health care providers, to collect HSCs together with mature immune cells from the blood of individuals with and without RA. We are in a unique position to collect samples from patients at initial diagnosis and before they begin their treatment course. This strategy has never been tested before, and will allow us to observe RA-triggering defects in these cells at very early stages of the disease. Specifically, we will use multiple genomics methods to test these patient stem cells and define the role of immune cells and their precursors in RA. In the short term, these findings will help to develop personalized approaches to inform the choice of treatment to avoid trial and error in patients. In the longer term, our efforts may lead to the re-purposing and development of novel drugs.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
493308
Name
Mancini Mathieu
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Epigenetic and transcriptional reprogramming of hematopoietic stem cells as a driver of rheumatoid arthritis onset and progression
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$90,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Assay For Transposase-Accessible Chromatin (Atac) Sequencing; Cell Indexing Of Transcripts And Epitopes (Cite) Sequencing; Epigenetics; Hematopoietic Stem Cells; Inflammation; Innate Immunity; Myeloid Cells; Rheumatoid Arthritis; Single Cell Rna Sequencing; Transcriptomics
Abstract
Rheumatoid arthritis (RA) affects 1 out of every 100 adult Canadians. RA is an autoimmune disease where the body's tissues are mistakenly attacked by their own immune cells. Anyone can develop RA and at any age, although it affects three times more women than men. RA causes chronic and painful inflammation of the joints, but can also damage other parts of the body (lungs, heart, arteries) to impair quality of life and shorten lifespan. Effective treatments of RA control inflammation but are not curative; some RA patients do not improve with treatment. We aim to determine the biological mechanisms that drive inflammation and trigger RA in patients, as a way to provide new therapeutic options for these patients. We will address this problem in a new way by looking for defects in hematopoietic stem and progenitor cells (HSCs)-cells that continuously replenish our pool of mature immune cells. Therefore, if mature immune cells carry over defects from their earlier predecessors, could they be responsible for causing inflammation in RA? Could we treat RA by correcting these dysfunctional, re-wired HSCs? I propose to tackle this problem differently, together with patients and health care providers, to collect HSCs together with mature immune cells from the blood of individuals with and without RA. We are in a unique position to collect samples from patients at initial diagnosis and before they begin their treatment course. This strategy has never been tested before, and will allow us to observe RA-triggering defects in these cells at very early stages of the disease. Specifically, we will use multiple genomics methods to test these patient stem cells and define the role of immune cells and their precursors in RA. In the short term, these findings will help to develop personalized approaches to inform the choice of treatment to avoid trial and error in patients. In the longer term, our efforts may lead to the re-purposing and development of novel drugs.
Competitiondate
202310
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Mancini, Mathieu
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $90,000~ $0~